<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4861">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01890902</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-110-002</org_study_id>
    <nct_id>NCT01890902</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee</brief_title>
  <official_title>A Randomized, Multicenter, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imprimis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imprimis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess analgesic efficacy  of Impracor (Ketoprofen
      10% Cream) compared to placebo for acute pain associated with OA flare of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary endpoint will be measured by changes in WOMAC pain subscale scores calculated by comparing baseline WOMAC pain subscale scores on Day 1 to the average WOMAC Pain Subscale scores on Day 4, 6, and 8.</measure>
    <time_frame>Day 4, 6 and 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment of knee arthritis using the modified Patient Overall Health Assessment from Day 1 to Day 8.</measure>
    <time_frame>Day 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Pain (Flare) Associated With Osteoarthritis (OA) of the Knee</condition>
  <arm_group>
    <arm_group_label>Impracor (Ketoprofen 10% Cream)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical Cream over a period of 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cream:</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Cream over a period of 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen 10% Cream</intervention_name>
    <arm_group_label>Impracor (Ketoprofen 10% Cream)</arm_group_label>
    <other_name>Impracor</other_name>
    <other_name>IPI-110</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Cream:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of OA of the knee according to the ACR criteria.

          -  Kellgren-Lawrence grade 2-3 disease

          -  Be willing to stop taking all analgesics including NSAIDs and opioids for the
             duration of the study, with exception of study-specified rescue medication.

        Exclusion Criteria:

          -  Total knee replacement surgery tentatively scheduled within next 6 months.

          -  Palpable knee effusion.

          -  Significant pain outside the target knee, including significant hip, back, or
             contralateral knee pain.

          -  Any type of orthopedic and/or prosthetic device or any skin abnormalities on the
             target knee that would prevent evaluations of local tolerability.

          -  History of asthma, rheumatoid arthritis, chronic inflammatory disease (e.g.,
             colitis), or fibromyalgia.

          -  History of gastrointestinal bleeding or peptic ulcer disease within the past 3 years.

          -  Have a positive urine drug test for illegal drug substances, non-prescribed
             controlled substances, or alcohol at screening.

          -  Acute or chronic illness that in the opinion of the investigator could compromise the
             integrity of study data or place the subject at risk by participating in the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ketoprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
